Efficacy and Adverse Reactions of Montelukast Sodium Chewable Tablets Combined with Inhaled Budesonide Suspension for the Treatment of Pediatric Asthma
Objective To explore the effect of montelukast sodium chewable tablets combined with inhaled budesonide suspension in the treatment of pediatric asthma.Methods A total of 88 children with asthma treated in Yicheng District People's Hospital from March 2021 to May 2023 were selected as the study objects,and they were divided into a control group and an observation group according to random number table method,with 44 cases in each group.The control group was treated with Inhaled budesonide suspension,and the observation group was treated with Montelukast sodium chewable tablet based on the control group.The clinical efficacy,inflammatory factors,pulmonary function indexes,immune function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.73%,which was higher than 79.55%of the control group,the difference was statistically significant(P＜0.05).After treatment,interleukin-8,tumor necrosis factor-α and interleukin-4 in observation group were lower than those in control group,and the differences were statistically significant(P＜0.05);the maximum expiratory flow,forced expiratory volume in the first second and forced vital capacity in the observation group were higher than those in the control group,with statistical significance(P＜0.05);immunoglobulin G and immunoglobulin A in the observation group were higher than those in the control group,and the differences between the two groups were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The use of montelukast sodium chewable tablets combined with inhaled budesonide suspension in children with asthma can reduce inflammatory factors,significantly improve lung and liver function,and have fewer adverse reactions,indicating good safety.
NETL
NSTL
万方数据
